

TABULA RASA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

	Year Ended December 31,	
	2019	2018
Cash flows from operating activities:		
Net loss	\$ (32,436)	\$ (47,269)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:		
Depreciation and amortization	34,276	16,802
Amortization of deferred financing costs and debt discount	10,877	103
Deferred taxes	(16,353)	(3,648)
Stock-based compensation	27,278	10,361
Change in fair value of acquisition-related contingent consideration	3,816	49,468
Acquisition-related contingent consideration paid	(24,480)	—
Other noncash items	20	51
Changes in operating assets and liabilities, net of effect from acquisitions:		
Accounts receivable, net	1,444	(9,456)
Inventories	(106)	(799)
Prepaid expenses and other current assets	(7,705)	(1,651)
Other assets	(269)	(460)
Accounts payable	(7,809)	(778)
Accrued expenses and other liabilities	5,712	2,599
Other long-term liabilities	(80)	507
Net cash (used in) provided by operating activities	<u>(5,815)</u>	<u>15,830</u>
Cash flows from investing activities:		
Purchases of property and equipment	(7,474)	(4,988)
Software development costs	(14,487)	(5,558)
Purchases of intangible assets	(1,202)	(30)
Issuance of note receivable	—	(1,000)
Proceeds from repayment of note receivable	1,000	—
Acquisitions of businesses, net of cash acquired	(158,762)	(32,232)
Net cash used in investing activities	<u>(180,925)</u>	<u>(43,808)</u>
Cash flows from financing activities:		
Payments for repurchase of common stock	—	(2,866)
Proceeds from exercise of stock options	3,702	3,523
Proceeds from disgorgement of short swing profits	—	156
Payments for debt financing costs	(9,630)	(175)
Borrowings on line of credit	—	45,000
Repayments of line of credit	(45,000)	—
Payments of equity offering costs	—	(364)
Payments of acquisition-related contingent consideration	(29,062)	(1,646)
Repayments of long-term debt and finance leases	(968)	(1,051)
Proceeds from issuance of convertible senior subordinated notes	325,000	—
Proceeds from sale of warrants	65,910	—
Purchase of convertible note hedges	(101,660)	—
Net cash provided by financing activities	<u>208,292</u>	<u>42,577</u>
Net increase in cash and restricted cash	21,552	14,599
Cash and restricted cash, beginning of year	25,029	10,430
Cash and restricted cash, end of year	<u>\$ 46,581</u>	<u>\$ 25,029</u>